within Pharmacolibrary.Drugs.ATC.P;

model P01CA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.417,
    Cl             = 12.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1800 / 1000000,
    adminCount     = 1,
    Vd             = 0.312,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0011166666666666666,
    Tlag           = 26.4
  );

  annotation(Documentation(
    info ="<html><body><p>Fexinidazole is an oral nitroimidazole-based medication indicated for the treatment of human African trypanosomiasis (sleeping sickness), caused by Trypanosoma brucei gambiense. It is the first all-oral regimen for this disease and was approved by the European Medicines Agency and WHO for this indication. It is used in both first and second stage disease.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following oral administration of fexinidazole in adult patients with sleeping sickness. Parameters are based on PopPK modeling in infected individuals (adults) from a phase II/III clinical study.</p><h4>References</h4><ol><li><p>Burrell-Saward, H, et al., &amp; Croft, SL (2017). Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis. <i>International journal of antimicrobial agents</i> 50(2) 203–209. DOI:<a href=&quot;https://doi.org/10.1016/j.ijantimicag.2017.01.038&quot;>10.1016/j.ijantimicag.2017.01.038</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28552771/&quot;>https://pubmed.ncbi.nlm.nih.gov/28552771</a></p></li><li><p>Torreele, E, et al., &amp; Pécoul, B (2010). Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. <i>PLoS neglected tropical diseases</i> 4(12) e923–None. DOI:<a href=&quot;https://doi.org/10.1371/journal.pntd.0000923&quot;>10.1371/journal.pntd.0000923</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21200426/&quot;>https://pubmed.ncbi.nlm.nih.gov/21200426</a></p></li><li><p>Kaiser, M, et al., &amp; Brun, R (2011). Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. <i>Antimicrobial agents and chemotherapy</i> 55(12) 5602–5608. DOI:<a href=&quot;https://doi.org/10.1128/AAC.00246-11&quot;>10.1128/AAC.00246-11</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21911566/&quot;>https://pubmed.ncbi.nlm.nih.gov/21911566</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end P01CA03;
